ArticleEBioMedicine2020
Genetic risk for dengue hemorrhagic fever and dengue fever in multiple ancestries.
Article in EBioMedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Host genetic factors modulating dengue virus: a systematic review of TLR polymorphisms.BMC infectious diseases · 2026Pooled it
- Dengue Fever and Its Burden in Burkina Faso: An Overview.Reviews in medical virology · 2026Review
- Dengue encephalitis: what's new?Current opinion in infectious diseases · 2025Review
- Genetic Susceptibility to Tuberculosis and the Utility of Polygenic Scores in Population Stratification.International journal of molecular sciences · 2025Review
- Severity of Primary and Secondary Dengue Virus 1 Infections: A Hospital-Based Study in Puerto Rico, 2012-2014.The American journal of tropical medicine and hygiene · 2025Article
- Identification of HLA ligands in dengue patients by multiplex PCR-SSP method.Molecular biology reports · 2025Article
- Comprehensive analysis of intervention and control studies for the computational identification of dengue biomarker genes.PLoS neglected tropical diseases · 2025Article
- An integrated approach to predict genetic risk for Mosquito-Borne diseases in the local Population of Tehsil Haripur, Khyber Pakhtunkhwa, Pakistan.Scientific reports · 2025Article
- Estimating the Number of Polygenic Diseases Among Six Mutually Exclusive Entities of Non-Tumors and Cancer.International journal of molecular sciences · 2024Review
- The Dynamic Relationship between Dengue Virus and the Human Cutaneous Innate Immune Response.Viruses · 2024Review
- Vav proteins do not influence dengue virus replication but are associated with induction of phospho-ERK, IL-6, and viperin mRNA following DENV infectionMicrobiology spectrum · 2024Article
- Serum Cortisol as a Biomarker of Severe Dengue.Tropical medicine and infectious disease · 2023Article
- Uncovering the Burden of Dengue in Africa: Considerations on Magnitude, Misdiagnosis, and Ancestry.Viruses · 2022Review
- Host genetics and infectious disease: new tools, insights and translational opportunities.Nature reviews. Genetics · 2021Review
- What Will Happen to Biomedical Research in Low-and-Middle Income Countries in the PostCOVID-19 World?Current tropical medicine reports · 2021Review
Corrections and comments
- Erratum issued
Authors and funding
34 authors at 14 institutions in 11 countries.
Funding
Abstract
backgroundGenetic risk factors for dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS) and dengue fever (DF) are limited, in particular there are sparse data on genetic risk across diverse populations.
methodsWe conducted a genome-wide association study (GWAS) in a derivation and validation sample of 7, 460 participants of Latin American, South Asian, and South East Asian ancestries. We then developed a weighted polygenic risk score (PRS) for each participant in each of the validation cohorts of the three ancestries to predict the risk of DHF/DSS compared to DF, DHF/DSS compared to controls, and, DF compared to controls.
findingsThe risk of DHF/DSS was significantly increased, odds ratio [OR] 1.84 (95%CI 1.47 to 2.31) (195 SNPs), compared to DF, fourth PRS quartile versus first quartile, in the validation cohort. The risk of DHF/DSS compared to controls was increased (OR=3.94; 95% CI 2.84 to 5.45) (278 SNPs), as was the risk of DF compared to controls (OR=1.97; 95%CI 1.63 to 2.39) (251 SNPs). Risk increased in a dose-dependent manner with increase in quartiles of PRS across comparisons. Significant associations persisted for PRS built within ancestries and applied to the same or different ancestries as well as for PRS built for one outcome (DHF/DSS or DF) and applied to the other.
interpretationThere is a strong genetic effect that predisposes to risk of DHF/DSS and DF. The genetic risk for DHF/DSS is higher than that for DF when compared to controls, and this effect persists across multiple ancestries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.